GET DAILY SIGNALSImmunovant (IMVT) Analyst Targets Point to +40% Upside Potential
Key Takeaways
- The central target of $49 is the arithmetic mean of the most recent verified analyst price targets for Immunovant, Inc. (IMVT), which average roughly $49 across the Street.
- With the stock near $35 at the time of writing, reaching $49 implies a gain of roughly 40%, a very large move that would push shares toward the upper end of their 52-week range.
- Published analyst targets span a wide range from about $30 to $66, reflecting sharply divergent views on the company's anti-FcRn drug candidate, IMVT-1402.
- The strongest support is the validated FcRn mechanism, a clean tolerability profile, and pivotal Graves' disease and myasthenia gravis readouts expected in 2027.
- The biggest risks are mixed rheumatoid arthritis data, a narrowed pipeline, no revenue, ongoing cash burn, and an undefined regulatory path.
- For more context, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
What Analysts Are Saying
Immunovant is a clinical-stage immunology company developing IMVT-1402, a fully human monoclonal antibody that inhibits the neonatal Fc receptor (FcRn) to reduce disease-driving IgG antibodies. The stock carries a "Buy" consensus across roughly 17 analysts, and the arithmetic mean of recent verified price targets is approximately $49, with individual targets spanning from about $30 to $66. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Views are unusually wide because analysts are pricing different outcomes for a pre-revenue pipeline. On the bullish side, Bank of America (Dina Ramadane) and Wells Fargo (Derek Archila) both carry $45 targets, JPMorgan holds an Overweight rating with a $50 target, LifeSci Capital (Sam Slutsky) sits at $53, Oppenheimer at $54, Citi near $57, and Piper Sandler at the high end near $66. Cautious voices include Bernstein at $37, Goldman Sachs at $32, and Truist Financial at about $30, reflecting skepticism about whether the pivotal programs will succeed. The dispersion means the $49 central target should be read as a probability-weighted midpoint, not a guarantee.
Current Market Position
At roughly $35, shares would need to appreciate close to 40% to reach $49, a very large move. The stock trades within a 52-week range of about $21 to $45, so $49 sits above the prior high and would require a new all-time-high break. Reaching it likely depends on positive pivotal data rather than gradual re-rating, because Immunovant has no product revenue and is valued almost entirely on IMVT-1402.
In its fiscal second quarter reported in early November, the company posted a narrower-than-expected loss and announced that IMVT-1402 600 mg met the primary endpoint (ACR20 at Week 28) in a potentially registrational difficult-to-treat rheumatoid arthritis (D2T RA) trial. However, the 300 mg dose did not separate from placebo and secondary endpoints missed statistical significance, leaving the regulatory path undefined pending FDA discussions.
Factors That Could Support a Move Higher
The FcRn mechanism is clinically validated by commercial drugs such as argenx's Vyvgart and UCB's Rystiggo in myasthenia gravis. IMVT-1402 is designed to deliver deep IgG reduction while minimizing the LDL cholesterol and albumin effects that troubled Immunovant's earlier candidate, batoclimab. The company held roughly $722 million in cash as of September 30, 2026, enough to fund operations toward a potential Graves' disease launch, and management reports strong enrollment in Graves' disease studies with pivotal readouts expected in 2027. A clean safety profile and positive analyst revisions following the RA data support the bullish case.
Key Risks to Consider
The 300 mg dose's failure and missed secondary endpoints raise questions about whether the 600 mg signal will replicate in Phase 3. The pipeline has narrowed: a cutaneous lupus proof-of-concept study missed its primary endpoint, and management now views further Sjögren's development as unlikely beyond the ongoing Phase 2 trial. With no revenue and a net loss of roughly $97 million in the latest quarter, the company remains dependent on cash reserves and future financing. Binary 2027 readouts, competitive FcRn programs, and potential regulatory hurdles all represent meaningful downside risks.
Technical Levels Worth Watching
The 52-week range of roughly $21 to $45 is the key structural reference. The prior high near $45 acts as major resistance, and $49 would represent a breakout into uncharted territory. The round-number $30 level has served as a notable floor during 2026, while the post-earnings jump toward $35 has placed shares in the middle of the range. A sustained move above $45 would be the first meaningful technical confirmation of a path toward the analyst-derived target.
Time Horizon and Catalysts Ahead
Analyst price targets typically reflect a roughly 12-month research horizon, though no single uniform date applies across firms. The most consequential catalysts are the pivotal Graves' disease and myasthenia gravis data expected in 2027, the FDA discussions on the D2T RA registration path, and any further pipeline or financing updates. Investors should watch analyst target revisions, cash burn, and enrollment updates, as well as an investor day scheduled for December 2026.
Monitoring the Stock with AI Tools
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals can provide an additional layer of insight when tracking names like this one. I’ve found them useful for spotting shifts in technical behavior and market conditions without having to review everything manually each day.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMVT's Indicator enters downward trend
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 226 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 226 cases the stock moved lower. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
IMVT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Oscillator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMVT as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 33 of 44 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.575) is normal, around the industry mean (3.498). P/E Ratio (-10.865) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.
Industry Biotechnology
Advertisement